Results 121 to 130 of about 4,245 (206)

[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)].

, 2015
This document describes the guideline for peptide receptor radionuclide therapy (PRRT) published by the German Society of Nuclear Medicine (DGN) and accepted by the Association of the Scientific Medical Societies in Germany (AWMF) to be included in the ...
Poeppel, T D;Boy, C;Bockisch, A;Kotzerke, J;Buchmann, I;Ezziddin, S;Scheidhauer, K;Krause, B J;Schmidt, D;Amthauer, H;Rösch, F;Nagarajah, J;Führer, D;Lahner, H;Pöpperl, G;Hörsch, D;Walter, M A;Baum, R P
core  

Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Somatostatin receptors (SSTR) are overexpressed by most neuroendocrine tumors (NETs), and patients with SSTR-positive disease can be identified by DOTA-peptide PET.
Albano, Domenico, Bodei, Lisa, De Rimini, Maria Luisa, Bartolomei, Mirco, Maccauro, Marco, Bauckneht, Matteo, Urso, Luca, Baldari, Sergio, Versari, Annibale, Filice, Angelina, Laudicella, Riccardo, Grana, Chiara Maria   +11 more
core   +1 more source

¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence. [PDF]

Endocr Oncol
Shekhda KM, Armeni E, Xu Y, D'afflitto M, Hayes A, Mandair D, Yu D, Quigley AM, Navalkissoor S, Gnanasegaran G, Grossman AB, Caplin M, Toumpanakis C, Khoo B.   +13 more
europepmc   +1 more source

Clinical Outcomes of Peptide Receptor Radionuclide Therapy in Japanese Patients with Metastatic Rectal Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Iizuka T, Kobayashi N, Wild D, Kaul F, Suzuki H, Maehara K, Okubo N, Tsuyuki S, Takano S, Kurita Y, Yoneda M, Ichikawa Y.   +11 more
europepmc   +1 more source

Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors. [PDF]

JCO Precis Oncol
Bogdani C, Karimi A, Li R, Atkinson EC, Oberstein PE, Siolas D.   +5 more
europepmc   +1 more source

My Life as a "Theranostician": A commentary on the evolution of theranostics. [PDF]

Npj Imaging
Hicks RJ.
europepmc   +1 more source

Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions. [PDF]

Eur J Nucl Med Mol Imaging
Virgolini IJ, Di Santo G, Santo G.
europepmc   +1 more source

Radiopharmaceutical Theranostics in Primary Adrenal Malignancies: A Surgeon's Perspective. [PDF]

Pharmaceuticals (Basel)
Laskou S, Geropoulos G, Radu PA, Pirvu C, Surlin V, Kosmidis C, Psarras K, Pantea S, Strambu V, Sapalidis K.   +9 more
europepmc   +1 more source

Reproductive and sexual sequelae of neuroendocrine tumour therapies: an under-recognised challenge. [PDF]

Endocr Relat Cancer
Shekhda KM, Shah PM, Biddanda A, Grossman A, Caplin M.   +4 more
europepmc   +1 more source

Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing ¹⁷⁷Lu-Based Peptide Receptor Radionuclide Therapy. [PDF]

Cancers (Basel)
Baur S, Ruhwedel T, Böke E, Kobus Z, Lishkova G, Wetz C, Amthauer H, Roderburg C, Tacke F, Rogasch JM, Samek W, Jann H, Ma J, Eschrich J.   +13 more
europepmc   +1 more source